These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36010890)

  • 1. Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting.
    Kamal M; Navai N; Bree KK; Williams LA; Cleeland CS; Shen SE; Wang XS
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN).
    Wang XS; Shi Q; Williams LA; Cleeland CS; Garcia-Gonzalez A; Chen TY; Shahid DR; Ramirez PT; Iniesta MD; Siverand AM; Meyer LA
    Gynecol Oncol; 2019 Mar; 152(3):492-500. PubMed ID: 30876494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a patient-reported outcome tool for assessing symptom burden during perioperative care in liver surgery: The MDASI-PeriOp-Hep.
    Wang XS; Shi Q; Williams LA; Lillemoe HA; Chen TY; Gottumukkala V; Garcia-Gonzalez A; Malveaux D; Kamal M; Cleeland CS; Aloia TA
    Eur J Oncol Nurs; 2021 Jun; 52():101959. PubMed ID: 33964632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translation and validation of the Chinese version of the MD Anderson symptom inventory for measuring perioperative symptom burden in patients with gynecologic cancer.
    Zhang T; Zheng YY; Yang ZR; Shi Q; Wang XS; Zhao J; Yang M; Wu CL; Wang GR
    BMC Womens Health; 2021 Jul; 21(1):276. PubMed ID: 34325677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI).
    Wang XS; Williams LA; Eng C; Mendoza TR; Shah NA; Kirkendoll KJ; Shah PK; Trask PC; Palos GR; Cleeland CS
    Cancer; 2010 Apr; 116(8):2053-63. PubMed ID: 20166216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Patient-Reported Symptom and Functional Outcomes to Indicate Recovery after First 90 Days of Radical Cystectomy: A Longitudinal Study.
    Wang XS; Bree KK; Navai N; Kamal M; Shen SE; Letona E; Cleeland CS; Shi Q; Gottumukkala V
    Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37297013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory.
    Mendoza TR; Wang XS; Lu C; Palos GR; Liao Z; Mobley GM; Kapoor S; Cleeland CS
    Oncologist; 2011; 16(2):217-27. PubMed ID: 21285393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module.
    Piil K; Whisenant M; Mendoza T; Armstrong T; Cleeland C; Nordentoft S; Williams LA; Jarden M
    Neurooncol Pract; 2021 Apr; 8(2):137-147. PubMed ID: 33898047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation and Application of the MD Anderson Symptom Inventory for Traditional Chinese Medicine (MDASI-TCM).
    Li Z; Shi Q; Liu M; Jia L; He B; Yang Y; Liu J; Lin H; Lin HK; Li P; Wang XS
    J Natl Cancer Inst Monogr; 2017 Nov; 2017(52):. PubMed ID: 29140491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The validity and utility of the M. D. Anderson Symptom Inventory in patients with breast cancer: evidence from the symptom outcomes and practice patterns data from the eastern cooperative oncology group.
    Mendoza TR; Zhao F; Cleeland CS; Wagner LI; Patrick-Miller LJ; Fisch MJ
    Clin Breast Cancer; 2013 Oct; 13(5):325-34. PubMed ID: 23816985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer.
    Sailors MH; Bodurka DC; Gning I; Ramondetta LM; Williams LA; Mendoza TR; Agarwal S; Sun CC; Cleeland CS
    Gynecol Oncol; 2013 Aug; 130(2):323-8. PubMed ID: 23685012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module.
    Armstrong TS; Gning I; Mendoza TR; Vera-Bolanos E; Gilbert MR; Rhines LD; Weinberg JS; Sanchez-Williams G; Levin V; Burton AW; Cleeland C
    J Neurosurg Spine; 2010 Apr; 12(4):421-30. PubMed ID: 20367379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy.
    Wang XS; Srour SA; Mendoza T; Whisenant M; Subbiah I; Gonzalez E; Kamal M; Shen SE; Cleeland C; Kebriaei P; Rezvani K; Neelapu S; Ahmed S; Shpall E
    Br J Haematol; 2023 May; 201(4):738-746. PubMed ID: 36733986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory.
    Gning I; Trask PC; Mendoza TR; Harle MT; Gutierrez KA; Kitaka SA; Sherman SI; Cleeland CS
    Oncology; 2009; 76(1):59-68. PubMed ID: 19052478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID).
    Williams LA; Whisenant MS; Mendoza TR; Peek AE; Malveaux D; Griffin DK; Ponce DA; Granwehr BP; Sheshadri A; Hutcheson KA; Ali SM; Peterson SK; Heymach JV; Cleeland CS; Subbiah IM
    J Patient Rep Outcomes; 2023 May; 7(1):48. PubMed ID: 37237077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
    Mendoza TR; Williams LA; Keating KN; Siegel J; Elbi C; Nowak AK; Hassan R; Cuffel B; Cleeland CS
    J Patient Rep Outcomes; 2019 Jun; 3(1):34. PubMed ID: 31209661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module.
    Tanaka S; Sato I; Takahashi M; Armstrong TS; Cleeland CS; Mendoza TR; Mukasa A; Takayanagi S; Narita Y; Kamibeppu K; Saito N
    Jpn J Clin Oncol; 2020 Jul; 50(7):787-793. PubMed ID: 32280995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the Spanish version of the MD Anderson symptom inventory - heart failure (MDASI-HF-Spanish) module.
    Fadol A; Buitrago J; Diaz MC; Shelton V; Harty C; Mendoza TR
    Cardiooncology; 2019; 5():19. PubMed ID: 32154025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the M. D. Anderson Symptom Inventory multiple myeloma module.
    Jones D; Vichaya EG; Wang XS; Williams LA; Shah ND; Thomas SK; Johnson VE; Champlin RE; Cleeland CS; Mendoza TR
    J Hematol Oncol; 2013 Feb; 6():13. PubMed ID: 23384030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes after oncologic hepatic resection predict the risk of delayed readiness to return to intended oncologic therapy (RIOT).
    Wang XS; Shi Q; Shen SE; Letona E; Kamal M; Cleeland CS; Aloia T; Gottumukkala V
    Eur J Surg Oncol; 2024 Jul; 50(7):108396. PubMed ID: 38754314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.